EZH2 and cancer: Previous studies have confirmed that multiple EZH2 targets in cancers (Table 1) belong to the cell cycle protein dependent kinase inhibitor (CKI) family, which negatively regulates the cell cycle (Kim and Roberts, 2016; Sha et al., 2016; Zhao et al., 2016; Tabbal et al., 2019; Wang et al., 2019).